Treatment of acute and recurrent vulvovaginal candidiasis (VVC/rVVC) - State of art in 2008. Expert Board of Polish Gynecological Society;Stanowisko zespołu ekspertów Polskiego Towarzystwa Ginekologicznego w sprawie leczenia ostrego i nawrotowego grzybiczego zapalenia pochwy i sromu - Stan wiedzy na 2008 rok

Ginekologia Polska

Volumn 79, Issue 9, 2008, Pages 638-652

  Kotarski, Jan ^a   Drews, Krzysztof ^b   Melszka, Romuald ^d   Rechberger, Tomasz ^b   Woroń, Jarosław ^c   Tomaszewski, Jacek ^b  

^a Novo Nordisk Pharma Ltd   (Poland)

^b NOVO NORDISK A S   (Denmark)

^c Sanofi Aventis

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 55849123246     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Bauters T, Dhont M, Temmerman M, [et al.]. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol. 2002, 187, 569-574.
2. Berg A, Heidrich F, Fihn S, {et al.]. Establishing the cuase of genitourinary symptoms in women in a family practive. Comparison of clinical examination and comprehensive microbiology. JAMA, 1984, 251, 620-625.
3. Bisschop M, Merkus J, Scheygrond H, [et al.]. Co-treatment of the male partner in vaginal candidosis: a double blind randomised control study. Br J Obstet Gynaecol. 1986; 93: 79-81
4. Brion L, Uko S, Goldman D. Risk of resistence associated with fluconazole prophylaxis: systematic review. J Infection. 2007, 54, 521-529.
5. Campomori A, Bonati M. Fluconazole treatment for vulvovaginal candidiasis during pregnancy. Ann Pharmacother. 1997, 31, 118-119.
6. Canuto M, Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002, 2, 550-563.
7. Carter T, Druschel Ch, Romitti P, et al.]. Anftifungal drugs and the risk of selected birth defects. Am J Obstet Gynecol. 2008, 198, 191, e1-e7.
8. Carvalho L, Bacellar O, Neves N, [et al.]. Downregulation of IFN-gamma production in patients with recurrent vaginal candidiasis. J Allergy Clin Immunol. 2002, 109, 102-105.
9. Cetin M, Ocak S, Gungoren A, [et al.]. Distribution of Candida species in women with vulvogaginal symptoms and their association with different ages and contraceptive methods. Scand J Infect Dis. 2007, 39, 584-588.
10. Cha R, Sobel J. Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther. 2004, 2, 357-366.
11. Consolaro M, Albertoni T, Svidzinski A, [et al.]. Vulvoginal candidiasis is associated with the production of germ by Candida albicans. Mycopathologia. 2005, 159, 501-507.
12. Coric M, Passos X, Miranda A, [et al.]. Correlation of in vitro itraconazole and fluconazole sporadic and recurrent vulvovaginal candidiasis. Int J Gynaecol Obstet. 2006, 95, 171-172.
13. Costa M, Passos X, Miranda A, [et al.]. Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis. Mycopathologia. 2004, 157, 43-47.
14. Daniels D, Forster G. AGUM/MSSVD national guideline on the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases): Radcliffe K, I. Ahmed J, Welch M, [et al.]. http://www.agum.org.uk/guidelines.htm
15. Dennerstein G. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med. 1986, 31, 801-803.
16. DePunzio C, Garutti P, Mollica G, [et al.]. Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. Eur J Obstet Gynecol Reprod Biol. 2003, 106, 193-197.
17. Eckert L, Hawes S, Stevens C, [et al.]. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998, 92, 757-765.
18. Ferahbas A, Koc A, Uksal U, [et al.]. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis. Am J Ther. 2006, 13, 332-336.
19. Fisher J. Candiduria: When and how to treat it. Curr Infection Dis Rep. 2000, 2, 523-550.
20. Geiger A, Foxman B. Risk factors in vulvovaginal candidiasis: a case-control study among university students. Epidemioloy. 1996, 7, 182-187.
21. Goswami, D, Goswami R, Banerjee U, [et al.]. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect. 2006, 52, 111-117.
22. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis. A prescrition-event monitoring study, with special reference to outcome of pregnancy. Eur J Clin Pharmacol. 1994, 46, 115-118.
23. Jick S. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy. 1999, 19, 221-222.
24. Kwaśniewska J, Jaskółowska A, Choczaj-Kukuła A. Kandydoza narzadów płciowych u partnerów seksualnych: zakażenia wiellogniskowe. Mikol Lek 2005, 12, 237-241.
25. Lupetti A, Danesi R, Campa M, [et al.]. Molecular basis of resistance to azole antifungals. Trens Mol Med. 2002, 8, 76-81.
26. M↠h P, Novikova N, Stukalova E. Colonisation of extragenital sites by Candida in women with recurrent vulvovaginal candidosis. BJOG. 2003, 110, 934-937.
27. Mastroiacovo P, Mazzone T, Botto L, [et al.]. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconzole. Am J Obstet Gynecol. 1996, 175, 1645-1650.
28. Menegola E, Broccia M, Di Renzo F, [et al.]. Antifungal triazoles induce malformations in vitro. Reprod Toxicol. 2001, 15, 421-427.
29. Mikamo H, Kawazoe K, Sato Y, [et al.]. Antifungal triazoles induce malformations in vitro Reprod Toxicol. 2001, 15, 421-427.
30. Mikamo K, Kawazoe K, Sato Y, [et al.]. Penetration of oral fluconazole into gynecological tissues. Antimicrob Agents Chemother. 1999, 43, 148,51.
31. Odds F. Candidosis of the Genitalia. In: Candida and Candidosis: a Review and Bibliography. 2nd ed. Ed. Odds F. London: Bailliere Tindall, 1988, 124-135.
32. Patel D, Gillespie B, Sobel J. [et al.]. Risk factors for reccurent vulvoginal cardidiasis in women receiving maintenance antifungal therapy: results of a prospective cohorts study. Am J Obstet Gynecol. 2004, 190, 644-653.
33. Piratta M, Gunn J, Chandros P. Not frush again Womens's experience of past-anthiotic anthiotic wovaginitis. Med J Aust. 2003, 179, 43-46.
34. Atsouni E, Cvazzo Ch, Halagas M. Traconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidates in nonpregnant women: a metaanalysis of randomized controlled trial. Am J Obstet Gynecol. 2008, 198, 153-160.
35. Reef S, Levine W, McNeil M, [et al.]. Treatment options for vulvovaginal candidates 1993. Clin Infect Dis. 1995, 20, Suppl. 1, 580-590.
36. Rees T, Phillips R. Multicenter comparison of one-day oral theraphy with fluconazole or ovaconazole in vaginal candidates, Int J Gynecol Obstet. 1992, 37, 33-38.
37. Rekamendacje Zespolu Ekspectow Polskiego Towarzystwa Ginekologicznego datyczace leczenia drazdizewych zakareh stroma i activity Ginekol Dypl. 2008, 2, 75-77.
38. Rekamendacje Zesauko Eksaectów Polkiego Towarzystwa Ginekologicznego dotyczace leczenia dradzakowych zakazeh seamd i pachwy u kobiet W: Uraginekologia Aratizcna. Med Bechthomer C. Cublin: Biochim. 2007.
39. Agg O, M. Metzger W. Recurrent allergic vulvoraginities treatment with Candida africans allergen immunotheraphy. Am J Obstet Gynecol. 1990, 162, 332-336.
40. Rogers T. Antifungal drug resistance: limited data, dramatic imnpact Int J Antimicrobial Agents. 2006, 27, Suppl 1, S7-S11.
41. Rosat, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginitis drug theraphy Obstet Gynecol. 1987, 69, 751-755.
42. Rosedale N, Browne K. Hyposensitisation in the management of recurring vaginal cardidiasis. Ann Allergy. 1979, 43, 250-253.
43. Rubin P, Wilton L, Imman W. Fluroconazole and pregnancy: reults of a prescription event-monitoring study. Int J Obstet Gynecol. 1992, 37, 25-27.
44. Say P. Jacyntino C. Difficult-to-manage vaginitis. Clin Obstet Gynecol. 2005, 48, 753-758.
45. Schutre G. Antifungal agents for the treatment of systemie mytoses. Sem Pediatr Infect. Diss. 2001, 12, 216-253.
46. Sexually Transmitted Diseases Treatment Guidelines 2006. Recommendations and Report. MMWR. 2006, 55, 1-100, http://www.cdc.govtstd/ treatment/2006/5511.pdf
47. Sobel J. Vaginities. N Engl J Med. 1993, 337, 1896-1903.
48. Sobel J, Wiesentied H, Martens M, [et al.]. Maintenance ticonazole theraphy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004, 351, 876-883.
49. Sobel J, Chaim W, Leaman O. Recurrent vulvovaginal candidates associated with long-term tamoxifen treatment in postmenopausal women. Obstet Gynecol. 1998, 38, 104-106.
50. Sobel J, Eura S, Lance B, [et al]. Vulvovaginal candidiasis: epidemiologic, diagnostics, and therapeutic considerations. Am J Obstet Gynecol. 1998, 178, 203-211.
51. Sobel J, Lundstrom T. Management of candidasia. Curr Urol Rep. 2001, 2, 321-325.
52. Sobel J, Candida glabrata: an important fungal pathogen for the 21 Century. Clin Microbiol. Newsletter. 2001, 23, 171-176.
53. Sobel J. Management of asymptomatic candiduria. Int J Microbial Agents. 1999, 11, 285-288
54. Sobel J. Management of infections caused by candida glabrata. Curr Int Dis Rep. 2000, 2, 424-428.
55. Sobel J. Vulvovaginal candidosis. Lancet. 2007, 369, 1961-1971.
56. Sojakova M, Liptajova D, Bararsky M. [et al.]. Fluconazole and draconazole susceptibility of vaginal yeast isolates from Slovakia. Mycopathologia. 2004, 153, 163-8169.
57. Soni N, Wagstaff, A. Fungal infection. Curr Anaesth Crit Care. 2005, 16, 231-241.
58. Sorensen H, Nielsen G, Olesen C, [et al.]. Ask of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol. 48, 234-238.
59. Spinillo A, Carratta L, Azzolt G, [et al.]. Recurrent vaginal candidates. Results of a cohort study of sexual transmission and intestinal reservoir. J Reprod Med. 1992, 37, 343-347.
60. Spinillo A, Caloma L, Piazzi G, [et al.]. Managing recurrent vulvovaginal candidiasis Entermittent presentation with tiraconazole. J Reprod Med. 1997, 42, 83-87.
61. Tomaszewisk I. Estrogenaterapia dopachwowa - crytophia kobie no menopauzie Przeg Menop. 2008, 3, 158-167.
62. Tomaszewski J, Molta P. Dioceaze moctwy - rota praniatykow w uronekologii. W: ukoginekologia praktyczna. Red. Rechherger T. Tublin: BiFolium. 2007, 149-153.
63. Tomaszewski J, Postawski K, Rechberger T. Kontrowersje datyzace roli estrogenow uroginekologie. W: Ukoginekologia praktycna. Red. Rechberger T. Lubalin: Bifollium. 2007, 169-183.
64. Targerson R. Marnach M, Bruce A [et al.]. Oral and vulva changes in pregnancy. Clin Dermatol. 2006, 24, 122-132.
65. Vensel H. Fluconazole: a valuable fungistatic: Print Care Update Ob Gyns. 2002, 9, 181-183.
66. Ventolini G, Baggistr M., Post-menopausal: recurrent vaginal candidates: effect of hysterectomy on response treatment: type of colonization and recurrence rates post-treatment. Maturitas. 2005, 51, 294-298.
67. Ventolini G, Baggish M. Recurrent vulvovaginal candidiasis. Clin Microbiol News. 2006, 28, 93-95.
68. Watson M, Grimshaw J, Band C, [et al]. Great versus intra-vaginal indicazole triazole anti-fungal treatment of uncomplicated vulvoginal candidiasis (thrush). Cochrane Database Syst Rev. 2001, 4, CD 004845.
69. Wadley P, Higgins S. Comparison of dotimazole, Baconazole and intraconazole in vaginal candidiasis. Br J Clin Pract. 1995, 49, 65-66.
70. Wichlewska M, Swoboda-Kopet E, Robasz A. [et al.]. Epidimiology clinical isolates of Candida albicans and their susceptibility to triazodes. Int J Antimicrob Agents 2002, 20, 472-273.
71. Young G, Jewell D. Topical treatment for vaginal candidiasis in pregnancy. Cochrane Database Syst. Rev. 2000, CD000225.
72. Yushasioglu D, Unal J, Yilmaz S, [et al.]. Genotoxicity testing of fluconazole in vivo and in vitro. Mutat Res. 2008, 603, 155-160.